EUVIMEDPoznaj EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY 4.0

Postprandial dysfunction in fatty liver disease

Josephine Grandt, Anne-Sofie H Jensen, Mikkel P Werge, Elias B Rashu, Andreas Møller, Anders E Junker, Lise Hobolth, Christian Mortensen, Christian D Johansen, Mogens Vyberg, Reza Rafiolsadat Serizawa, Søren Møller and 2 more

Physiological Reports · 2023

DOI: 10.14814/phy2.15653 ↗

At a glance

Randomisierte kontrollierte Studie in Physiological Reports, 2023. Written by Josephine Grandt and 13 co-authors. Institution: Gastro Unit, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark. Major MEDLINE topics: Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2, Insulin Resistance. Cited 14 times so far (Crossref); 39 references. The full text is freely available (open access, CC BY 4.0). Funded by: Danmarks Frie Forskningsfond, European Foundation for the Study of Diabetes, Novo Nordisk Fonden.

AbstraktSubjectsDane bibliograficzneCiteRelated studies

Abstract (original language)

Fatty liver disease has mainly been characterized under fasting conditions. However, as the liver is essential for postprandial homeostasis, identifying postprandial disturbances may be important. Here, we investigated postprandial changes in markers of metabolic dysfunction between healthy individuals, obese individuals with non‐alcoholic fatty liver disease (NAFLD) and patients with cirrhosis. We included individuals with biopsy‐proven NAFLD ( n = 9, mean age 50 years, mean BMI 35 kg/m 2 , no/mild fibrosis), cirrhosis with hepatic steatosis ( n = 10, age 62 years, BMI 32 kg/m 2 , CHILD A/B) and healthy controls ( n = 10, age 23, BMI 25 kg/m 2 ), randomized 1:1 to fasting or standardized mixed meal test (postprandial). None of the patients randomized to mixed meal test had type 2 diabetes (T2D). Peripheral blood was collected for 120 min. After 60 min, a transjugular liver biopsy and liver vein blood was taken. Plasma levels of glucose, insulin, C‐peptide, glucagon, and fibroblast growth factor 21 (FGF21) were measured. Postprandial peak glucose and C‐peptide were significantly increased in NAFLD, and cirrhosis compared with healthy. Patients with NAFLD and cirrhosis had hyperglucagonemia as a potential sign of glucagon resistance. FGF21 was increased in NAFLD and cirrhosis independent of sampling from the liver vein versus peripheral blood. Glucagon levels were higher in the liver vein compared with peripheral blood. Patients with NAFLD and cirrhosis without T2D showed impaired glucose tolerance, hyperinsulinemia, and hyperglucagonemia after a meal compared to healthy individual. Postprandial characterization of patients with NAFLD may be important to capture their metabolic health.

Subjects

MeSH terms (MEDLINE)

Non-alcoholic Fatty Liver DiseaseDiabetes Mellitus, Type 2Insulin ResistanceHumansMiddle AgedYoung AdultAdultGlucagonC-PeptideLiverGlucoseLiver Cirrhosis

Substances

GlucagonC-PeptideGlucose

Authors and institutions

  • Gastro Unit, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark.
  • Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
  • Department of Pathology, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark.
  • Center for RNA Medicine, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark.
  • Department of Clinical Physiology and Nuclear Medicine, Center for Functional and Diagnostic Imaging and Research, Copenhagen University Hospital, Hvidovre, Denmark.

ORCID profiles: Nicolai J Wewer Albrechtsen

Funding

  • Danmarks Frie Forskningsfond
  • European Foundation for the Study of Diabetes
  • Novo Nordisk Fonden

Cite

APA

Grandt, J., Jensen, A. H., Werge, M. P., Rashu, E. B., Møller, A., Junker, A. E., Hobolth, L., Mortensen, C., Johansen, C. D., Vyberg, M., Serizawa, R. R., Møller, S., Gluud, L. L., & Wewer Albrechtsen, N. J. (2023). Postprandial dysfunction in fatty liver disease. Physiological Reports. https://doi.org/10.14814/phy2.15653

Vancouver

Grandt J, Jensen AH, Werge MP, Rashu EB, Møller A, Junker AE, et al. Postprandial dysfunction in fatty liver disease. Physiological Reports. 2023. doi:10.14814/phy2.15653

BibTeX
@article{Grandt2023,
  author = {Grandt, Josephine and Jensen, Anne-Sofie H and Werge, Mikkel P and Rashu, Elias B and Møller, Andreas and Junker, Anders E and Hobolth, Lise and Mortensen, Christian and Johansen, Christian D and Vyberg, Mogens and Serizawa, Reza Rafiolsadat and Møller, Søren and Gluud, Lise Lotte and Wewer Albrechtsen, Nicolai J},
  title = {Postprandial dysfunction in fatty liver disease},
  journal = {Physiological Reports},
  year = {2023},
  doi = {10.14814/phy2.15653}
}
Start for free →